Page last updated: 2024-11-02

oxidopamine and Dysarthosis

oxidopamine has been researched along with Dysarthosis in 1 studies

Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).

Research Excerpts

ExcerptRelevanceReference
"Motor symptoms of Parkinson's disease (PD) follow the degeneration of dopaminergic neurons in the substantia nigra pars compacta."1.43Deep brain stimulation exacerbates hypokinetic dysarthria in a rat model of Parkinson's disease. ( Anderson, CJ; Dorval, AD; King, NO, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
King, NO1
Anderson, CJ1
Dorval, AD1

Other Studies

1 other study available for oxidopamine and Dysarthosis

ArticleYear
Deep brain stimulation exacerbates hypokinetic dysarthria in a rat model of Parkinson's disease.
    Journal of neuroscience research, 2016, Volume: 94, Issue:2

    Topics: Adrenergic Agents; Analysis of Variance; Animals; Deep Brain Stimulation; Disease Models, Animal; Dy

2016